These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19695416)

  • 1. Testing new ideas: is a picture worth a thousand words?
    Yealy DM; Callaham ML
    Ann Emerg Med; 2009 Sep; 54(3):337-8. PubMed ID: 19695416
    [No Abstract]   [Full Text] [Related]  

  • 2. A hundred (and one) graphs tell only part of the story.
    Silbergleit R
    Ann Emerg Med; 2009 Sep; 54(3):342-3. PubMed ID: 19695418
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "A graphic reanalysis of the NINDS Trial".
    Dewey HM; Churilov L; Blacker D; Bladin C; Davis SM; Donnan GA; Gates P; Gerraty RP; Hand P; Levi C; Lindley RI; Markus R; Read S
    Ann Emerg Med; 2010 Feb; 55(2):227-9; author reply 229. PubMed ID: 20116035
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombolysis in stroke: still not ready for community hospital use by emergency physicians.
    McNamara RM
    Ann Emerg Med; 2009 Sep; 54(3):339-41. PubMed ID: 19695417
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to: "A graphic reanalysis of the NINDS Trial".
    Saver JL; Gornbein J; Starkman S
    Ann Emerg Med; 2010 Feb; 55(2):226-7; author reply 229. PubMed ID: 20116034
    [No Abstract]   [Full Text] [Related]  

  • 6. Be careful when extrapolating trial data to real life.
    Dudley N
    BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525900
    [No Abstract]   [Full Text] [Related]  

  • 7. A graphic reanalysis of the NINDS Trial.
    Hoffman JR; Schriger DL
    Ann Emerg Med; 2009 Sep; 54(3):329-36, 336.e1-35. PubMed ID: 19464756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Mann J
    Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689
    [No Abstract]   [Full Text] [Related]  

  • 9. NINDS Reanalysis Committee's reanalysis of the NINDS trial.
    Mann J
    Stroke; 2005 Feb; 36(2):230-1; author reply 230-1. PubMed ID: 15637327
    [No Abstract]   [Full Text] [Related]  

  • 10. Stroking the data: re-analysis of the NINDS trial.
    Magid D; Naviaux N; Wears RL
    Ann Emerg Med; 2005 Apr; 45(4):385-7. PubMed ID: 15795716
    [No Abstract]   [Full Text] [Related]  

  • 11. Alteplase for stroke. Financial information is needed to ensure objectivity.
    Solomon RC
    BMJ; 2002 Jun; 324(7353):1581; author reply 1581. PubMed ID: 12092607
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute stroke treatment: thrombolysis.
    Bogousslavsky J; Paciaroni M; Gallai V
    Cerebrovasc Dis; 2000; 10 Suppl 4():14-6. PubMed ID: 11070393
    [No Abstract]   [Full Text] [Related]  

  • 13. Alteplase for acute stroke revisited: the first 10 years.
    Lyden PD; Lees KR; Davis SM
    Lancet Neurol; 2006 Sep; 5(9):722-4. PubMed ID: 16914399
    [No Abstract]   [Full Text] [Related]  

  • 14. Why were the benefits of tPA exaggerated?
    Trotter G
    West J Med; 2002 May; 176(3):194-7. PubMed ID: 12016246
    [No Abstract]   [Full Text] [Related]  

  • 15. Alteplase for patients with ictus: the dilemma persists.
    Alegre EJ; Ríos E
    Stroke; 2007 Sep; 38(9):e91. PubMed ID: 17673727
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardioembolic stroke in the THRombolysis and STatins (THRaST) study.
    Cappellari M; Bovi P; Toni D; Micheletti N; Tomelleri G; Carletti M; Moretto G
    Int J Stroke; 2015 Feb; 10(2):E22. PubMed ID: 25598034
    [No Abstract]   [Full Text] [Related]  

  • 17. 4.5 hours: the new time window for tissue plasminogen activator in stroke.
    Davis SM; Donnan GA
    Stroke; 2009 Jun; 40(6):2266-7. PubMed ID: 19407232
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue plasminogen activator approved for stroke.
    Barber A; Gommans J
    N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.
    Wechsler LR; Jovin TG
    Stroke; 2012 Sep; 43(9):2517-9. PubMed ID: 22910892
    [No Abstract]   [Full Text] [Related]  

  • 20. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.